News & Updates

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD
Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD
16 Jun 2023

Among women with inflammatory bowel disease (IBD), those who have long-term immunomodulator exposure are at increased risk of high-grade cervical intraepithelial neoplasia and cervical cancer (CIN2+), according to a study.

Cumulative immunomodulator exposure may heighten risk of CIN2+ in IBD
16 Jun 2023